B. Lynne Parshall - 18 Jan 2022 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Role
Director
Signature
By: Patrick R. O'Neil, attorney-in-fact For: B. Lynne Parshall
Issuer symbol
IONS
Transactions as of
18 Jan 2022
Net transactions value
-$49,758
Form type
4
Filing time
20 Jan 2022, 19:21:24 UTC
Previous filing
05 Nov 2021
Next filing
11 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IONS Common Stock Options Exercise $0 +5,754 +7.8% $0.000000 79,132 18 Jan 2022 Direct F1
transaction IONS Common Stock Tax liability $49,758 -1,652 -2.1% $30.12 77,480 18 Jan 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IONS Restricted Stock Unit Options Exercise $0 -5,754 -37% $0.000000 9,775 18 Jan 2022 Common Stock 5,754 $0.000000 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.
F2 Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
F3 Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
F4 Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.